Harbor Health Care ETF MEDI
Set alert
As of Oct 30, 1:17 PM ET
- YTD
- +11.93%
- 1 year
- +17.03%
- Open
- 35.73
- Prev close
- 35.29
- Mkt cap
- 23.59M
- Vol
- 5.06K
- Avg vol
- 4.60K
- EPS
- 1.20
- P/E
- 29.45
- Div yield
- 0.00%
More statistics
- Low
- 35.20
- High
- 35.76
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 26.44
- 200-d avg
- 26.40
News
1 month ago benzinga.com
Why Is Ascendis Pharma Stock Trading Lower on Tuesday?
Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates a $400 million share repurchase program.
4 months ago feeds.benzinga.com
Why Is Legend Biotech Stock Falling Thursday?
Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get the latest technical levels here.
4 months ago benzinga.com
Why Is Legend Biotech Stock Falling Thursday?
Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get the latest technical levels here.
4 months ago zacks.com
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
7 months ago benzinga.com
Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints
Rhythm Pharmaceuticals says EMANATE trial misses goals, despite BMI reduction signals and continued pipeline development plans.
7 months ago seekingalpha.com
Harbor Health Care ETF Q4 2025 Portfolio Review
Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly…
7 months ago seekingalpha.com
Harbor Health Care ETF Q4 2025 Commentary
During the fourth quarter, the Harbor Health Care ETF returned 10.43% (NAV), underperforming the Russell 3000® Growth Health Care Index, which returned 16.71%. The underperformance was primarily…
9 months ago benzinga.com
Why Your Pneumonia Shot Is About To Get A Massive Upgrade
Vaxcyte shares rise after starting Phase 3 trials for its VAX-31 pneumonia vaccine, expanding studies in adults and infants while planning major U.S. manufacturing investments.
9 months ago seekingalpha.com
Harbor Health Care ETF Q3 2025 Commentary
During the third quarter, the Harbor Health Care ETF returned 7.30% (NAV), outperforming the Russell 3000® Growth Health Care Index, which returned 3.80%. We purchased IDEXX Laboratories, a MedTech…
11 months ago benzinga.com
Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs
A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.
1 year ago seekingalpha.com
MEDI Group Readies $15 Million U.S. IPO Plan
MEDI Group has filed for a $15 million US IPO, but its revenue is declining from a small base, with negative free cash flow and increased cash used in operations. The IPO valuation appears excessive,…
1 year ago seekingalpha.com
Harbor Health Care ETF Q1 2025 Commentary
The Health Care sector rebounded in the first quarter of 2025, navigating a volatile but opportunistic landscape. During the first quarter, the Harbor Health Care ETF returned 2.18% (NAV),…
-
2 years ago benzinga.com
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
Over half of US states have high levels of Covid-19 in wastewater as President Biden isolates with virus. New vaccines expected by Sept.
2 years ago zacks.com
ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat
Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.
2 years ago zacks.com
UnitedHealth Beats on Q4 Earnings, Shares Slip: ETFs in Focus
The largest U.S. health insurer UnitedHealth Group (UNH) reported better-than-expected fourth-quarter 2023 results but medical costs rose more than expected for the first time in two years.
2 years ago zacks.com
Eli Lilly Beats on Q3 Earnings: ETFs to Buy
Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.
3 years ago zacks.com
UnitedHealth Beats on Q3 Earnings, Raises View: ETFs to Gain
UnitedHealth (UNH) reported better-than-expected third-quarter 2023 results. Earnings and revenues breezed past the Zacks Consensus Estimate.
3 years ago zacks.com
Eli Lilly Soars on Blockbuster Q2 Earnings: ETFs to Tap
Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 earnings report and an optimistic outlook. ETFs…
3 years ago zacks.com
UnitedHealth Beats Q2 Earnings, Updates View: ETFs to Gain
UnitedHealth (UNH) reported better-than-expected second-quarter 2023 results, breezing past the Zacks Consensus Estimate for earnings and revenues. The company lifted the lower end of its full-year…
3 years ago zacks.com
ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics
Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline,…
3 years ago etftrends.com
Harbor CIO Kristof Gleich: Thematics Help Advisors Connect With Clients
Thematic investments are seeing a resurgence in investor interest after developing a – perhaps undeserved and unwarranted – negative reputation in recent years. The economic regime has shifted, and…
3 years ago etftrends.com
3 Ways to Play iShares' 2023 Hot Takes With ETFs
These are the questions on every investor's mind: Have markets really priced in the severity of the Fed's campaign against inflation? How bad would a 2023 recession be — if there is one at all?
3 years ago etftrends.com
Harbor Launches Active Pure Play Healthcare ETF: MEDI
Harbor Capital Advisors has launched a new active, fully transparent ETF, providing advisors the opportunity to invest in a pure play healthcare strategy.